Clinical trials: Placebo Group
Atrophy, Vaginal Diseases
A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
- Trial name
- NCT00276094
- Testing
- Ospemifene 30 mg, Ospemifene 60 mg, Nonhormonal vaginal lubricant
- Volunteers
- 826 people
- Sponsor
- Shionogi
Multiple Sclerosis, Relapsing-Remitting
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis
The purpose of this study is to determine whether the use of EGb 761 by patients with Relapsing-Remitting Multiple Sclerosis is effective in improving cognition, when compared to placebo.
- Trial name
- NCT00276341
- Testing
- EGb 761® (Tanakan®)
- Where
- 30 sites in France
- Volunteers
- 47 people
- Sponsor
- Ipsen
Epilepsy, Focal
A Study of Brivaracetam in Subjects With Partial Onset Seizures
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy
- Trial name
- NCT00175929
- Testing
- Brivaracetam
- Where
- 56 sites in Belgium, Czechia and 7 more
- Volunteers
- 157 people
- Sponsor
- UCB Pharma
Asthma
A Study of MEMP1972A in the Prevention of Allergen-Induced Airway Obstruction in Patients With Mild Asthma (SOLARIO)
This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety and tolerability of MEMP1972A when administered to patients by intravenous (IV) infusion for the…
- Trial name
- NCT01196039
- Testing
- MEMP1972A
- Where
- 7 sites in Canada, Sweden
- Volunteers
- 29 people
- Sponsor
- Genentech, Inc.
Cystic Fibrosis
Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
This study will evaluate the efficacy and safety of CTP-656 in patients with cystic fibrosis (CF) who have a cystic fibrosis transmembrane conductance regulator (CFTR) gating mutation.
- Trial name
- NCT02971839
- Testing
- VX-561, IVA
- Where
- 14 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cannabis Use Disorder
Cannabidiol: a Novel Intervention for Cannabis Use Problems?
The purpose of this trial is to investigate a novel treatment for cannabis dependence: cannabidiol. Between 96 and 168 young people who want to quit cannabis and meet criteria for moderate cannabis use disorder (DSM-5) will be…
- Trial name
- NCT02044809
- Testing
- Cannabidiol
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- University College, London
Healthy
Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429
The purpose is to study the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-04427429 administered intravenously to healthy adult volunteers
- Trial name
- NCT01117233
- Testing
- PF-04427429
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pain, Healthy
To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).
As a transition from preclinical investigations to clinical development in this first-in-human trial, safety, tolerability, and pharmacokinetics of BI 660848 will be assessed in human male volunteers using single rising oral…
- Trial name
- NCT01145014
- Testing
- BI 660848
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers
Investigation of safety and tolerability of BI 655088 following intravenous infusion of single rising doses and exploration of the pharmacokinetics and pharmacodynamics of BI 655088 after single dosing
- Trial name
- NCT02696616
- Testing
- BI 655088
- Where
- Belgium
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus
Evaluate the efficacy, safety and tolerability of a 12-week treatment of 4 doses of ASP1941 compared to placebo in combination with metformin in adult patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on…
- Trial name
- BALANCE (NCT01117584)
- Testing
- ipragliflozin, Metformin
- Where
- 44 sites in United States, Hungary and 4 more
- Volunteers
- 343 people
- Sponsor
- Astellas Pharma Inc
Healthy Volunteers
Cannabis Effects on Electroencephalography
Background: Tetrahydrocannabinol (THC) is a partial CB1/CB2 agonist and causes its pharmacological effects by binding to cannabinoid receptors.
- Trial name
- CEG (NCT04316598)
- Testing
- Cannabis Sativa
- Where
- Spain
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Parc de Salut Mar
Asthma
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects…
- Trial name
- NCT01165138
- Testing
- Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 70 sites in United States, Germany and 4 more
- Volunteers
- 612 people
- Sponsor
- GlaxoSmithKline
Gait or Balance Disorder Problems
The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow
Betahistine may provide benefit by enhancement of Cerebral Blood Flow (CBF). This placebo-controlled pharmacodynamic treatment study will primarily explore the effect of betahistine on cerebral blood flow measured by dynamic…
- Trial name
- CBF (NCT01468285)
- Testing
- betahistine dihydrochloride
- Where
- 2 sites in Singapore
- Volunteers
- 27 people
- Sponsor
- Abbott Products
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients
This is a randomised, double-blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics and dose response of multiple doses of GSK2269557 administered as a dry powder in COPD subjects.
- Trial name
- NCT02130635
- Testing
- GSK2269557 100 MCG, GSK2269557 500 MCG
- Where
- 2 sites in Germany
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Chronic Management of Body Weight
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
- Trial name
- NCT07670884
- Testing
- HRS9531 Tablet
- Where
- 2 sites in China
- Volunteers
- 675 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Healthy
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
The purpose of this study is to investigate safety, toleration and time course of plasma concentration of multiple oral doses of PF-06273340 for 14 days in healthy subjects of two age groups, aged 18-55 years (Group 1) and aged…
- Trial name
- NCT01934738
- Testing
- PF-06273340
- Where
- Belgium
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetic Neuropathy
Study of DA-9801 to Treat Diabetic Neuropathy
To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.
- Trial name
- NCT01822925
- Testing
- DA-9801 300mg, DA-9801 600mg, DA-9801 900mg
- Where
- 14 sites in United States
- Volunteers
- 128 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Uterine Myomas
PGL4001 Versus Placebo in Uterine Myomas
This trial will assess the efficacy and safety of PGL4001 with concomitant iron administration versus placebo with concomitant iron administration, over a 3-month period for the pre-operative treatment of pre-menopausal women…
- Trial name
- PEARLI (NCT00755755)
- Testing
- PGL4001 (ulipristal) and iron
- Where
- 38 sites in Czechia, Hungary and 4 more
- Volunteers
- 241 people
- Sponsor
- PregLem SA
Metabolic Syndrome
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
The purpose of this study is to compare the efficacy of treatment with rosuvastatin with atorvastatin in reducing Low density lipoprotein cholesterol over 6 weeks of treatment in subjects with metabolic syndrome.
- Trial name
- NCT00654485
- Testing
- Rosuvastatin, Atorvastatin
- Volunteers
- 940 people
- Sponsor
- AstraZeneca
Atopic Dermatitis (AD)
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
The primary objective of the study was to assess the efficacy of Dupilumab, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01979016
- Testing
- Dupilumab, Background treatment
- Where
- 4 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.